Plaque-Prevention Measures
A discussion on when to begin plaque-prevention measures and how to improve LDL levels with dieting.
Related Articles
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America
Familial chylomicronemia syndrome (FCS) is an ultrarare inherited disorder. Genetic testing is not always feasible or conclusive. European clinicians developed a “FCS score” to differentiate…
Choose Your Affiliation – NYU Health Sciences Library
Users with access to atnyulmc.org should login with their NYU Langone Credentials. Users with access to home.nyu.edu should login with their NYU Credentials. Still have…
Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association | Arteriosclerosis, Thrombosis, and Vascular Biology
Despite the availability of multiple classes of lipoprotein-lowering medications, some high-risk patients have persistent hypercholesterolemia and may require nonpharmacologic therapy. Lipoprotein apheresis (LA) is a…
Triglycerides Podcasts | Journals Gateway | American Diabetes Association
This special series of Diabetes Core Update is supported by an independent educational grant from Amarin Corp. For more than 30 years, statins have been…
Diabetes Core Update – Special Edition – Lipids Beyound Statins and LDL – Diabetes Core Update – Podcast en iVoox
In this special episode titled “Lipids – Beyond Statins and LDL Cholesterol”, our host, Dr. Neil Skolnik will discuss with two expert guests the details…
Choose Your Affiliation – NYU Health Sciences Library
Users with access to atnyulmc.org should login with their NYU Langone Credentials. Users with access to home.nyu.edu should login with their NYU Credentials. Still have…
Faster CAC Progression After Menopause May Warrant Intensified Therapy
Though the reasons aren’t clear, drops in estrogen likely play a significant role in accelerating plaque, says Matthew Budoff.
Expanded Label Officially Makes Bempedoic Acid a CVD Prevention Medication
New indications supported by CLEAR Outcomes trial
Effect of Statin Use on Liver Enzymes and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with the prevalence of approximately 30%.1 The prevalence goes up among specific high-risk populations:…